On March 4, 2019 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that James Dentzer, President and Chief Executive Officer, will present at the Cowen & Company 39th Annual Healthcare Conference on Wednesday, March 13th, at 11:20 a.m. – 11:50 a.m. EST in the Berkeley room at the Marriott Copley in Boston, MA (Press release, Curis, MAR 4, 2019, View Source [SID1234533927]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Company’s website: www.curis.com. The webcast will be archived for 90 days.

On March 4, 2019 Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Monday, March 11, 2019, at 2:10 p.m. EST at The Boston Marriott Copley Place (Press release, Heron Therapeutics, MAR 4, 2019, View Source [SID1234533944]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this presentation will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On March 4, 2019 Horizon Pharma plc (Nasdaq: HZNP) reported that it is offering to sell $300,000,000 of its ordinary shares in an underwritten public offering (Press release, Horizon Pharma, MAR 4, 2019, View Source [SID1234533961]). The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of ordinary shares in the public offering solely to cover over-allotments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citigroup, Morgan Stanley, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering.

The Company intends to use the net proceeds from this offering, together with cash on hand, to redeem or repay approximately $550 million of outstanding debt, consisting of a portion of the outstanding principal amount of term loans under the Company’s Credit Agreement and a portion of the outstanding principal amount of the Company’s 6.625% Senior Notes due 2023, as well as to pay the related premiums, accrued interest and fees and expenses associated with the planned redemption or repayment.

A registration statement relating to the ordinary shares described above was previously filed with and became effective by rule of the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at View Source Copies of the preliminary prospectus supplement and related prospectus, when available, may be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] or by phone at 800-831-9146; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department; Goldman Sachs & Co. LLC, c/o: Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected] or by phone at 866-471-2526; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department or by phone at 631-274-2806.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction, which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On March 3, 2019 3SBio Inc. ("3SBio") (HKEX: 1530) and Taiwan Liposome Company, Ltd. ("TLC") (Nasdaq: TLC, TWO: 4152) reported an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC’s proprietary NanoX technology platform in the therapeutic areas of oncology and severe infectious diseases (Press release, 3SBio, MAR 3, 2019, View Source [SID1234553911]). Under this alliance, TLC and 3SBio will cooperate to obtain regulatory approvals in mainland China, and TLC will utilize its commercial-scale manufacturing capabilities to supply the two liposomal products for 3SBio to commercialize in mainland China. The two companies also agreed to further collaboration in researching and developing other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology, and oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"3SBio’s partnership with TLC reflects the continuous execution of our strategy to introduce novel therapeutics which addresses significant unmet medical needs of cancer patients in China," said Dr. Jing Lou, Chairman and Chief Executive Officer of 3SBio. He added, "We intend to seek regulatory approval for the two liposomal products to treat patients with cancer and severe infectious diseases in the near future. We believe both candidates have strong commercial potential due to the lower toxicity profile of TLC’s liposomal formulations and will complement 3SBio’s oncology therapeutic and supportive care portfolio while leveraging 3SBio’s commercial platform with over 2,500 sales and marketing professionals across China."

Under the terms of the agreement, TLC is eligible to receive up to US$25 million in upfront payments for each product and subsequent regulatory and sales milestone payments. TLC is also eligible a share of the potential profits from product sales. Additional financial terms were not disclosed.

"We are excited to have 3SBio as a partner to collaborate on the advancement of our NanoX technology-based products," commented TLC President George Yeh. "This opportunity is an endorsement to the competency of our NanoX platform, which was applied to products that have been approved for sale in Taiwan. With this partnership, we are able to take full advantage of NanoX’s manufacturing capabilities to expand our commercial framework. We believe that 3SBio’s prominent position in China’s biotech industry, coupled with the commercial capacities at our contract manufacturing organizations’ facilities in Australia and Taiwan, will lead to the successful launch and commercialization of these products in mainland China."

On March 1, 2019 Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, reported that it has changed its name to Rakuten Medical, Inc (Press release, Rakuten Aspyrian, MAR 1, 2019, View Source/2019/02/28/rakuten-aspyrian-announces-name-change-to-rakuten-medical/" target="_blank" title="View Source/2019/02/28/rakuten-aspyrian-announces-name-change-to-rakuten-medical/" rel="nofollow">View Source [SID1234533855]). This name more closely reflects the company’s corporate purpose of creating a global biotechnology company integrating research and development with commercial operations in order to develop therapeutics that improve cancer patient outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are aiming to deliver PIT platform to as many cancer patients and as early as possible worldwide. Our new name that becomes effective today, Rakuten Medical, better aligns with our goal of developing a global brand that resonates within the pharmaceutical and medical device industries," said Mickey Mikitani, chairman and CEO of Rakuten Medical. "Despite our name change, our mission of ‘Conquering cancer, For life’ will not change. We are stronger today than ever before as we continue building the organization necessary to conquer cancer by developing innovative cancer treatments."

For more information, visit View Source